WO2017099494A8 - Genome editing composition comprising cpf1, and use thereof - Google Patents

Genome editing composition comprising cpf1, and use thereof Download PDF

Info

Publication number
WO2017099494A8
WO2017099494A8 PCT/KR2016/014379 KR2016014379W WO2017099494A8 WO 2017099494 A8 WO2017099494 A8 WO 2017099494A8 KR 2016014379 W KR2016014379 W KR 2016014379W WO 2017099494 A8 WO2017099494 A8 WO 2017099494A8
Authority
WO
WIPO (PCT)
Prior art keywords
genome editing
cpf1
editing composition
composition
technique
Prior art date
Application number
PCT/KR2016/014379
Other languages
French (fr)
Korean (ko)
Other versions
WO2017099494A1 (en
Inventor
김진수
허준호
김대식
김정은
김경미
김혜란
구태영
Original Assignee
기초과학연구원
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 기초과학연구원 filed Critical 기초과학연구원
Publication of WO2017099494A1 publication Critical patent/WO2017099494A1/en
Publication of WO2017099494A8 publication Critical patent/WO2017099494A8/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases RNAses, DNAses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression

Abstract

The present invention relates to a genome editing composition comprising Cpf1, a genome editing method using the same, and a technique for preparing transformed eukaryotic organisms.
PCT/KR2016/014379 2015-12-08 2016-12-07 Genome editing composition comprising cpf1, and use thereof WO2017099494A1 (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
KR20150174212 2015-12-08
KR10-2015-0174212 2015-12-08
US201662299043P 2016-02-24 2016-02-24
US62/299,043 2016-02-24
KR10-2016-0036381 2016-03-25
KR20160036381 2016-03-25

Publications (2)

Publication Number Publication Date
WO2017099494A1 WO2017099494A1 (en) 2017-06-15
WO2017099494A8 true WO2017099494A8 (en) 2017-08-10

Family

ID=59013788

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2016/014379 WO2017099494A1 (en) 2015-12-08 2016-12-07 Genome editing composition comprising cpf1, and use thereof

Country Status (2)

Country Link
KR (2) KR101897213B1 (en)
WO (1) WO2017099494A1 (en)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102380245B1 (en) 2013-11-07 2022-03-30 에디타스 메디신, 인코포레이티드 CRISPR-RELATED METHODS AND COMPOSITIONS WITH GOVERNING gRNAS
WO2016073990A2 (en) 2014-11-07 2016-05-12 Editas Medicine, Inc. Methods for improving crispr/cas-mediated genome-editing
CA2986310A1 (en) 2015-05-11 2016-11-17 Editas Medicine, Inc. Optimized crispr/cas9 systems and methods for gene editing in stem cells
US11911415B2 (en) 2015-06-09 2024-02-27 Editas Medicine, Inc. CRISPR/Cas-related methods and compositions for improving transplantation
WO2017053879A1 (en) 2015-09-24 2017-03-30 Editas Medicine, Inc. Use of exonucleases to improve crispr/cas-mediated genome editing
EP3433363A1 (en) 2016-03-25 2019-01-30 Editas Medicine, Inc. Genome editing systems comprising repair-modulating enzyme molecules and methods of their use
EP3443086B1 (en) 2016-04-13 2021-11-24 Editas Medicine, Inc. Cas9 fusion molecules, gene editing systems, and methods of use thereof
KR101961332B1 (en) * 2016-07-28 2019-03-22 기초과학연구원 Pharmaceutical Composition for Treating or Preventing Eye Disease Comprising Cas9 Protein and Guide RNA
CA3033939A1 (en) * 2016-08-19 2018-02-22 Toolgen Incorporated Artificially engineered angiogenesis regulatory system
US11499151B2 (en) 2017-04-28 2022-11-15 Editas Medicine, Inc. Methods and systems for analyzing guide RNA molecules
US10428319B2 (en) 2017-06-09 2019-10-01 Editas Medicine, Inc. Engineered Cas9 nucleases
US10011849B1 (en) 2017-06-23 2018-07-03 Inscripta, Inc. Nucleic acid-guided nucleases
US9982279B1 (en) 2017-06-23 2018-05-29 Inscripta, Inc. Nucleic acid-guided nucleases
EP3652312A1 (en) 2017-07-14 2020-05-20 Editas Medicine, Inc. Systems and methods for targeted integration and genome editing and detection thereof using integrated priming sites
CN111836894B (en) * 2017-11-21 2023-11-10 基恩科雷有限责任公司 Compositions for genome editing using CRISPR/Cpf1 systems and uses thereof
KR20200103769A (en) * 2018-01-23 2020-09-02 기초과학연구원 Extended single guide RNA and uses thereof
WO2019173942A1 (en) * 2018-03-12 2019-09-19 Nanjing Bioheng Biotech Co., Ltd Engineered chimeric guide rna and uses thereof
KR102177174B1 (en) 2018-05-18 2020-11-10 울산대학교 산학협력단 A retinal degenerated animal model by PDE6B gene deletion and the preparation method thereof
EP3830301A1 (en) 2018-08-01 2021-06-09 Mammoth Biosciences, Inc. Programmable nuclease compositions and methods of use thereof
WO2020032711A1 (en) * 2018-08-09 2020-02-13 (주)지플러스 생명과학 Novel crispr-associated protein and use thereof
WO2020030984A2 (en) 2018-08-09 2020-02-13 G+Flas Life Sciences Compositions and methods for genome engineering with cas12a proteins
CN109666684A (en) * 2018-12-25 2019-04-23 北京化工大学 A kind of CRISPR/Cas12a gene editing system and its application
EP3931313A2 (en) 2019-01-04 2022-01-05 Mammoth Biosciences, Inc. Programmable nuclease improvements and compositions and methods for nucleic acid amplification and detection
KR102493904B1 (en) 2019-12-13 2023-01-31 한국생명공학연구원 Immunodeficient Animal Model Mutated IL2Rg Gene by EeCpf1 and Method for Producing the same
KR102551876B1 (en) 2019-12-18 2023-07-05 한국생명공학연구원 Composition for Genome Editing or Inhibiting Gene Expression comprising Cpf1 and Chimeric DNA-RNA Guide
KR102471698B1 (en) * 2020-03-24 2022-11-28 연세대학교 산학협력단 Novel guide RNA and method for diagnosing Coronavirus disease 2019
WO2021194172A1 (en) * 2020-03-24 2021-09-30 연세대학교 산학협력단 Novel guide rna and method for diagnosing coronavirus infection 2019 using same
CN113373170A (en) * 2021-04-29 2021-09-10 江西农业大学 pFNCpfAb/pCrAb double-plasmid system and application thereof
CN113969281B (en) * 2021-12-24 2022-04-01 汕头大学 Modified CrRNA fragment and African swine fever virus kit
KR20240020336A (en) 2022-08-04 2024-02-15 성균관대학교산학협력단 Protospacer Adjacent Motif-independent mutant Cas9 protein

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110643600A (en) * 2012-10-23 2020-01-03 基因工具股份有限公司 System for cutting target DNA and use thereof
BR112016013201B1 (en) 2013-12-12 2023-01-31 The Broad Institute, Inc. USE OF A COMPOSITION COMPRISING A CRISPR-CAS SYSTEM IN THE TREATMENT OF A GENETIC OCULAR DISEASE
US9790490B2 (en) * 2015-06-18 2017-10-17 The Broad Institute Inc. CRISPR enzymes and systems

Also Published As

Publication number Publication date
KR20180028996A (en) 2018-03-19
KR101897213B1 (en) 2018-09-11
KR20170068400A (en) 2017-06-19
KR101958437B1 (en) 2019-03-15
WO2017099494A1 (en) 2017-06-15

Similar Documents

Publication Publication Date Title
WO2017099494A8 (en) Genome editing composition comprising cpf1, and use thereof
WO2017031360A8 (en) Capture of nucleic acids using a nucleic acid-guided nuclease-based system
LT3577110T (en) 8-oxetan-3-yl-3,8-diazabicyclo[3.2.1]octan-3-yl substituted compounds as hiv inhibitors
EP3691747A4 (en) Compositions and methods for editing rna
WO2015200902A8 (en) Endophytes, associated compositions, and methods of use thereof
EP3715461A4 (en) Genome editing composition using crispr/cpf1 system and use thereof
EP3271021A4 (en) Tat-induced crispr/endonuclease-based gene editing
EP3427822A4 (en) Catalyst for preparing 2,5-furancarboxylic acid and method for preparing 2,5-furancarboxylic acid using catalyst
EP3456825A4 (en) Plant genome editing method
WO2014144761A3 (en) Increasing specificity for rna-guided genome editing
EP3635119A4 (en) Compositions and methods for genome editing
IL282178A (en) Products, uses & methods
EP3322526A4 (en) Improved copper-containing multimetallic catalysts, and method for using the same to make biobased 1,2-propanediol
EP3594312A4 (en) Composition, method for producing same, and use thereof
WO2016108927A3 (en) Nitrification inhibitor compositions and methods for preparing the same
EP3552017A4 (en) Compounds, compositions and methods
WO2016033437A3 (en) Polyethers, polyamines, polythioethers, and methods for making same
EP3800994A4 (en) Genome editing in plants
GB202017595D0 (en) Compositions, and methods and uses relating thereto
IL284800A (en) Methods, uses & compositions
GB2577981B (en) Methods, products & Uses relating thereto
EP3366689A4 (en) Transition metal complexes, catalyst composition including the same and method for preparing polyolefin therewith
GB201813648D0 (en) Methods, products & uses relating thereto
EP3199526A4 (en) Intermediate for use in synthesizing paroxetine, preparation method for the intermediate, and uses thereof
EP3480188A4 (en) Method for preparing urate-anion exchanger 1 inhibitor

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16873359

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase in:

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 02/10/2018)

122 Ep: pct application non-entry in european phase

Ref document number: 16873359

Country of ref document: EP

Kind code of ref document: A1